These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 28233092)

  • 1. Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.
    Schnöder TM; Eberhardt J; Koehler M; Bierhoff HB; Weinert S; Pandey AD; Nimmagadda SC; Wolleschak D; Jöhrens K; Fischer T; Heidel FH
    J Cancer Res Clin Oncol; 2017 May; 143(5):807-820. PubMed ID: 28233092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
    de Melo Campos P; Machado-Neto JA; Eide CA; Savage SL; Scopim-Ribeiro R; da Silva Souza Duarte A; Favaro P; Lorand-Metze I; Costa FF; Tognon CE; Druker BJ; Olalla Saad ST; Traina F
    Oncotarget; 2016 Feb; 7(6):6948-59. PubMed ID: 26755644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
    Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
    Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].
    Chen YX; Li Y; Zhang LY; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1329-33. PubMed ID: 22040998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
    Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
    Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
    Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.
    Lewandowski K; Kanduła Z; Gniot M; Paczkowska E; Nawrocka PM; Wojtaszewska M; Janowski M; Mariak M; Handschuh L; Kozlowski P
    Ann Hematol; 2022 Dec; 101(12):2665-2677. PubMed ID: 36266510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.
    Ayad MW; Nafea D
    Genet Test Mol Biomarkers; 2011; 15(1-2):17-21. PubMed ID: 21034166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
    Sun T; Zhang L
    Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.
    Fleischman AG; Aichberger KJ; Luty SB; Bumm TG; Petersen CL; Doratotaj S; Vasudevan KB; LaTocha DH; Yang F; Press RD; Loriaux MM; Pahl HL; Silver RT; Agarwal A; O'Hare T; Druker BJ; Bagby GC; Deininger MW
    Blood; 2011 Dec; 118(24):6392-8. PubMed ID: 21860020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?
    Ramos TL; Sánchez-Abarca LI; Redondo A; Hernández-Hernández Á; Almeida AM; Puig N; Rodríguez C; Ortega R; Preciado S; Rico A; Muntión S; Porras JRG; Del Cañizo C; Sánchez-Guijo F
    Oncotarget; 2017 Apr; 8(17):28187-28202. PubMed ID: 28390197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
    Gurska LM; Okabe R; Schurer A; Tong MM; Soto M; Choi D; Ames K; Glushakow-Smith S; Montoya A; Tein E; Miles LA; Cheng H; Hankey-Giblin P; Levine RL; Goel S; Halmos B; Gritsman K
    Clin Cancer Res; 2023 Mar; 29(5):943-956. PubMed ID: 36537918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of IFN-α2b on COX-2 and Angiogenesis in JAK2V617F Mutation Myeloproliferative Neoplasms].
    Zhao YL; Zhang LJ; Fu JZ; Xu Q; Liu GM; Xie XL; Liang WT; Cheng ZY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Jul; 47(4):473-478. PubMed ID: 28591945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia.
    Rinaldi CR; Rinaldi P; Alagia A; Gemei M; Esposito N; Formiggini F; Martinelli V; Senyuk V; Nucifora G; Pane F
    Blood; 2010 Dec; 116(26):6023-6. PubMed ID: 20861460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.
    Bartalucci N; Tozzi L; Bogani C; Martinelli S; Rotunno G; Villeval JL; Vannucchi AM
    J Cell Mol Med; 2013 Nov; 17(11):1385-96. PubMed ID: 24237791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2V617F influences epigenomic changes in myeloproliferative neoplasms.
    Chen CC; Chiu CC; Lee KD; Hsu CC; Chen HC; Huang TH; Hsiao SH; Leu YW
    Biochem Biophys Res Commun; 2017 Dec; 494(3-4):470-476. PubMed ID: 29066347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
    Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
    Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOCS2: inhibitor of JAK2V617F-mediated signal transduction.
    Quentmeier H; Geffers R; Jost E; Macleod RA; Nagel S; Röhrs S; Romani J; Scherr M; Zaborski M; Drexler HG
    Leukemia; 2008 Dec; 22(12):2169-75. PubMed ID: 18769447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of Tyrosine Kinase 2 Does Not Affect the Severity of
    Yamaji T; Shide K; Kameda T; Sekine M; Kamiunten A; Hidaka T; Kubuki Y; Shimoda H; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Yamamoto S; Hasuike S; Nagata K; Shimoda K
    Anticancer Res; 2017 Jul; 37(7):3841-3847. PubMed ID: 28668884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [JAK2V617F mutation and p-STAT5 protein expression in peripheral blood cells of patients with myeloproliferative neoplasm and their relations with clinical features].
    Chen YX; Li Y; Zhang LY; Liu X; Shan NN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1398-404. PubMed ID: 23257441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.